## Jenny G H Low

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4251706/publications.pdf

Version: 2024-02-01

279701 223716 5,018 49 23 46 citations h-index g-index papers 55 55 55 11309 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature, 2020, 584, 457-462.	13.7	1,744
2	Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Reports, 2021, 34, 108728.	2.9	568
3	Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe, The, 2021, 2, e240-e249.	3.4	322
4	A Dynamic Immune Response Shapes COVID-19 Progression. Cell Host and Microbe, 2020, 27, 879-882.e2.	5.1	271
5	Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. Journal of Experimental Medicine, 2021, 218, .	4.2	259
6	Discovery and Genomic Characterization of a 382-Nucleotide Deletion in ORF7b and ORF8 during the Early Evolution of SARS-CoV-2. MBio, 2020, $11$ , .	1.8	245
7	Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). Nutrition, 2020, 79-80, 111017.	1.1	190
8	Current Status of Dengue Therapeutics Research and Development. Journal of Infectious Diseases, 2017, 215, S96-S102.	1.9	144
9	Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. Clinical Infectious Diseases, 2021, 73, e2932-e2942.	2.9	143
10	Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine, 2020, 58, 102911.	2.7	120
11	A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Molecular Therapy, 2021, 29, 1970-1983.	3.7	111
12	Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut, 2022, 71, 226-229.	6.1	109
13	Critically ill <scp>COVID</scp> â€19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability. American Journal of Hematology, 2020, 95, E156-E158.	2.0	90
14	Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nature Microbiology, 2016, 1, 16164.	5.9	75
15	<i>Flavivirus (i) serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells. Science Advances, 2018, 4, eaar4297.</i>	4.7	69
16	Coronavirus disease 2019 (COVID-19): an evidence map of medical literature. BMC Medical Research Methodology, 2020, 20, 177.	1.4	68
17	Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine, 2014, 32, 5041-5048.	1.7	63
18	Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients. PLoS Neglected Tropical Diseases, 2016, 10, e0004851.	1.3	53

#	Article	IF	CITATIONS
19	Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. Med, 2022, 3, 104-118.e4.	2.2	38
20	Mycotic Aneurysm Due to Burkholderia pseudomallei Infection: Case Reports and Literature Review. Clinical Infectious Diseases, 2005, 40, 193-198.	2.9	37
21	Induction of Human T-cell and Cytokine Responses Following Vaccination with a Novel Influenza Vaccine. Scientific Reports, 2018, 8, 18007.	1.6	33
22	Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated yellow fever infection. Nature Medicine, 2019, 25, 1218-1224.	15.2	33
23	Clinical and laboratory features of hypercoagulability in COVID-19 and other respiratory viral infections amongst predominantly younger adults with few comorbidities. Scientific Reports, 2021, 11, 1793.	1.6	28
24	Bioaerosol Sampling in Clinical Settings: A Promising, Noninvasive Approach for Detecting Respiratory Viruses. Open Forum Infectious Diseases, 2017, 4, ofw259.	0.4	26
25	Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination. Npj Vaccines, 2022, 7, 31.	2.9	21
26	Favorable vaccine-induced SARS-CoV-2–specific T cell response profile in patients undergoing immune-modifying therapies. Journal of Clinical Investigation, 2022, 132, .	3.9	20
27	Preclinical Antiviral Testing for Dengue Virus Infection in Mouse Models and Its Association with Clinical Studies. ACS Infectious Diseases, 2018, 4, 1048-1057.	1.8	17
28	Mimicking immune signatures of flavivirus infection with targeted adjuvants improves dengue subunit vaccine immunogenicity. Npj Vaccines, 2019, 4, 27.	2.9	14
29	Monitoring for Airborne Respiratory Viruses in a General Pediatric Ward in Singapore. Journal of Public Health Research, 2019, 8, jphr.2019.1407.	0.5	12
30	Low incidence of venous thrombosis but high incidence of arterial thrombotic complications among critically ill COVID-19 patients in Singapore. Thrombosis Journal, 2021, 19, 14.	0.9	10
31	Mycobacterium abscessus Infection During Ustekinumab Treatment in Crohn's Disease: A Case Report and Review of the Literature. Journal of Crohn's and Colitis, 2018, 12, 1505-1507.	0.6	8
32	A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations – results of a prematurely terminated study. Trials, 2018, 19, 305.	0.7	8
33	Dengueold disease, new challenges in an ageing population. Annals of the Academy of Medicine, Singapore, 2013, 42, 373-5.	0.2	8
34	Amplified parallel antigen rapid test for point-of-care salivary detection of SARS-CoV-2 with improved sensitivity. Mikrochimica Acta, 2022, 189, 14.	2.5	8
35	Feasibility and utility of facemask sampling in the detection of SARS-CoV-2 during an ongoing pandemic. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2489-2496.	1.3	7
36	Characteristics of acute febrile illness and determinants of illness recovery among adults presenting to Singapore primary care clinics. BMC Infectious Diseases, 2016, 16, 612.	1.3	6

#	Article	IF	CITATIONS
37	Disentangling etiologies of CNS infections in Singapore using multiple correspondence analysis and random forest. Scientific Reports, 2020, 10, 18219.	1.6	6
38	Bacillus Calmette–Guérin scar flare after an mRNA SARS-CoV-2 vaccine. Cmaj, 2021, 193, E1178-E1178.	0.9	5
39	Patterns of medication use and factors associated with antibiotic use among adult fever patients at Singapore primary care clinics. Antimicrobial Resistance and Infection Control, 2016, 5, 47.	1.5	3
40	A case report of invasive candidiasis and fungal osteomyelitis mimicking oropharyngeal carcinoma recurrence in an immunocompetent patient following transoral robotic surgery. International Journal of Surgery Case Reports, 2017, 35, 33-36.	0.2	3
41	Postâ€hospitalization venous thromboembolism in COVIDâ€19 patients: Evidence against routine postâ€hospitalization prophylactic anticoagulation. International Journal of Laboratory Hematology, 2022, 44, .	0.7	3
42	Multifactorial influences underpinning a decision on COVID-19 vaccination among healthcare workers: a qualitative analysis. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	2
43	Prognosticating Dengue. Clinical Infectious Diseases, 2017, 64, ciw867.	2.9	1
44	Etiology of febrile respiratory infections in the general adult population in Singapore, 2007–2013. Heliyon, 2021, 7, e06329.	1.4	1
45	Pericardial effusion and tamponade in a young woman. Annals of the Academy of Medicine, Singapore, 2022, 51, 129-131.	0.2	1
46	2505. A Novel Mobile Phone Application for Remote Research Data Collection is Effective in Monitoring Chronic Sequelae After Acute Viral Infections. Open Forum Infectious Diseases, 2018, 5, S753-S753.	0.4	0
47	626â€Dissecting the spatial heterogeneity of SARS-CoV-2-infected tumour microenvironment reveals a lymphocyte-dominant immune response in a HBV-associated HCC patient with COVID-19 history. , 2021, 9, A656-A656.		0
48	Thrombotic Complications in COVID-19 Patients: Low Incidence of Thrombotic Complications Among Critically Ill COVID-19 Patients in Singapore. Blood, 2020, 136, 37-38.	0.6	0
49	Re: Dengue fever outbreak: prevention possible (author's reply). Annals of the Academy of Medicine, Singapore, 2013, 42, 484.	0.2	O